Browse the evidence

Dysbiosis (specifically reduced SCFA-producing bacteria and increased pro-inflammatory taxa) contributes to the pathogenesis of Type 2 Diabetes through mechanisms involving gut permeability, LPS-driven inflammation, and impaired insulin signaling.

Maintaining gut health through a fiber-rich diet may help manage blood sugar levels by reducing inflammation and improving insulin sensitivity. This is particularly relevant for those with or at risk for Type 2 Diabetes.

Calculating the Area Under the Curve (AUC) ratio of the Insulinogenic Index (IGI) during a 70g carbohydrate meal tolerance test provides a superior evaluation of pancreatic beta-cell function and glucose variability compared to the Delta (increment) ratio method in Type 2 Diabetes Mellitus patients.

For Type 2 Diabetes patients undergoing a meal tolerance test with 70g of carbohydrates, using the Area Under the Curve (AUC) method to calculate the Insulinogenic Index provides a more reliable assessment of pancreatic function than the simpler Delta ratio method. This is because the AUC method shows less data overlap and stronger correlation with daily glucose variability, offering a clearer view of how the pancreas handles carbohydrate loads.

Automated dietary monitoring using social media data (text and images) is technically feasible and usable, but current accuracy levels (approx. 51% for fusion models) are insufficient for precise clinical nutrient tracking without manual verification.

Social media-based dietary apps can help you track food by reading your posts, but they are not yet accurate enough to rely on for precise calorie or nutrient counting. Use them as a rough guide or habit-builder, but verify specific nutritional needs manually or with a professional.

Saturated fat intake (8% of energy) is not associated with increased mortality or cardiovascular disease risk compared to higher fat intakes.

Do not fear saturated fat from whole food sources. The PURE study suggests that moderate saturated fat intake (around 8-10% of energy) is not associated with increased health risks. Focus on the overall quality of your diet, including the source of fats and carbohydrates.

Training to failure does not produce a repeated bout effect (RBE) that mitigates longitudinal fatigue or recovery differences over an 8-week period.

Training to failure does not seem to 'protect' you from future fatigue or soreness over time. If you choose to train to failure, expect similar fatigue levels to submaximal training in the long run, but potentially lower strength gains.

Proximity to failure does not significantly influence muscle hypertrophy, as hypertrophy outcomes were similar across all training groups despite differences in strength.

You do not need to train to failure to build muscle. This study found no clear difference in muscle growth between training close to failure and stopping well before failure. Focus on consistent volume and progressive overload rather than grinding out reps to failure.

Social Determinants of Health (SDoH), including socioeconomic status, neighborhood environment, and food access, are strongly associated with obesity prevalence and weight regain, independent of individual clinical factors.

Your environment matters. If you live in an area with limited access to healthy food or safe places to exercise, maintaining weight loss is significantly harder. Recognizing these external barriers can help you seek community resources or advocate for policy changes that support your health goals.

Intentional weight loss induces physiological adaptations in energy expenditure and intake that actively oppose weight maintenance, contributing to weight regain.

If you have lost weight, expect your body to fight to regain it through increased hunger and lower energy burn. This is a biological adaptation, not a character flaw. Successful maintenance likely requires strategies that address these specific physiological drivers, such as managing hunger cues and adjusting activity levels, rather than relying on willpower alone.

Orlistat is generally not recommended for people living with HIV on combined antiretroviral therapy (cART) due to the risk of reduced absorption of antiretroviral drugs and subsequent loss of viral control.

Do not take Orlistat if you are on HIV medication without explicit approval from your doctor. It can block the absorption of your HIV drugs, causing your viral load to rise. There are safer alternatives available.

Transoral outlet reduction (TORe) using argon plasma coagulation (APC) induces a significant increase in postprandial peptide YY (PYY) levels, particularly in patients who have undergone cholecystectomy, whereas APC combined with suturing does not produce this effect.

If you have regained weight after gastric bypass due to a stretched connection (anastomosis), endoscopic tightening with argon plasma coagulation (APC) may help restore your body's natural satiety signals, specifically Peptide YY (PYY). This effect is particularly strong if you have had your gallbladder removed. This suggests that choosing the right endoscopic technique (APC vs. suturing) matters for hormonal health and potentially long-term weight management.

Transoral outlet reduction (TORe) delays the postprandial decrease in ghrelin levels by approximately 30 minutes, shifting the nadir from 30 minutes to 60-90 minutes, without significantly altering the total ghrelin exposure (AUC) or correlating with clinical success.

TORe changes *when* you feel hungry after eating, not necessarily *how much* hunger hormone is produced overall. Specifically, it delays the drop in hunger hormones (ghrelin) by about 30 minutes. This might help you feel full a bit longer after a meal, but this specific hormonal change does not predict whether you will successfully lose weight.

One year after TORe, patients experience a significant overall decrease in postprandial Glucagon-like peptide-1 (GLP-1) levels, regardless of the specific technique used (APC vs. suture) or clinical success status.

After TORe, your levels of GLP-1 (a hormone that helps regulate blood sugar and satiety) tend to drop significantly one year later. Despite this drop, patients often still see improvements in blood sugar and lipids. This suggests that weight loss and other factors are more important for metabolic health than GLP-1 levels alone.

Gastric greater curvature plication combined with Nissen fundoplication (GGCP + Nissen) produces significantly less long-term weight loss and inferior glucose homeostasis compared to sleeve gastrectomy (SG) in patients with obesity and type 2 diabetes models, despite being effective for GERD resolution.

If you have obesity and significant acid reflux, standard sleeve gastrectomy might worsen your reflux. A combined procedure (plication + Nissen) can fix your reflux and provide moderate weight loss, but it is less effective for weight loss and blood sugar control than standard sleeve gastrectomy. Choose based on whether reflux control or maximum weight loss is your primary goal.

Self-managed lifestyle interventions (diet and exercise) are the primary initial weight loss strategy in China, but they result in low compliance and modest efficacy, leading to a high unmet need for anti-obesity medications (AOMs).

If you are in China and trying to lose weight, know that self-managed diet and exercise are the standard first steps, but they often fail due to low compliance. If lifestyle changes aren't working, it is not your fault; the current options have limitations. Discuss anti-obesity medications (AOMs) with your doctor, as new options are becoming available and are desired by both patients and physicians for better efficacy and safety.

Anti-obesity medications (AOMs) are underutilized in China due to limited approved options and physician preference for lifestyle interventions, despite high patient willingness to try new AOMs.

If you are a physician in China, be aware that AOMs are underutilized due to limited options and safety concerns. However, patients are willing to try new AOMs. As new AOMs become available, consider prescribing them for patients who fail lifestyle interventions.

GLP-1 receptor agonists (specifically liraglutide) exert direct anti-inflammatory and chondroprotective effects in osteoarthritis by suppressing NF-κB activation, reducing pro-inflammatory cytokines (IL-1β, IL-6, TNF-α), and downregulating cartilage-degrading enzymes (MMPs, ADAMTS), while promoting type II collagen synthesis.

Research shows that GLP-1 drugs may protect knee cartilage directly by reducing inflammation and stopping enzymes that break down joint tissue, in addition to helping you lose weight. This suggests these drugs might slow the progression of osteoarthritis, not just mask the pain.

GLP-1 receptor agonists reduce the incidence of knee surgeries and slow cartilage loss in patients with knee osteoarthritis and type 2 diabetes, as demonstrated in real-world observational cohorts.

For patients with knee OA and diabetes, using GLP-1 drugs like liraglutide or semaglutide is associated with a lower risk of needing knee surgery and slower loss of knee cartilage compared to not using these drugs. This suggests they may help preserve joint structure over time.

The gut microbiota causally influences obesity and metabolic disorders by modulating the secretion of gut hormones (GLP-1, ghrelin, PYY) and influencing hypothalamic neuroendocrine pathways, suggesting microbiota-based therapies as a potential treatment.

While microbiota-based therapies are still being researched, the gut microbiome plays a role in regulating appetite hormones like GLP-1 and ghrelin. Dietary patterns that support a healthy microbiome may contribute to better metabolic health and weight management.

GLP-1 receptor agonists (specifically Exendin-4, Liraglutide, and native GLP-1) modulate human mesenchymal stem cell (hMSC) function by promoting osteogenesis and inhibiting adipogenesis through context-, dose-, and timing-dependent mechanisms.

GLP-1 medications (like Ozempic or Trulicity) are primarily used for diabetes and weight loss, but research suggests they also interact with your body's stem cells. Specifically, they appear to encourage bone-forming cells to work better while discouraging fat-storing cells from differentiating. This effect depends heavily on the specific drug, the dose, and the timing of exposure. While this is promising for regenerative medicine, it is currently based on lab studies, not human clinical trials for tissue repair.

Ghrelin, the only gastrointestinal hormone that increases appetite, stimulates dopamine release in the VTA to increase food motivation and sex motivation in males, but reduces sex motivation in females during lactation.

Ghrelin increases hunger and food motivation by stimulating dopamine release in the brain. In males, it may also increase sex motivation, while in lactating females, it may reduce sex motivation to prioritize maternal care. Understanding these hormonal signals can help manage hunger and motivated behaviors.

During the stable weight maintenance phase, the appetite-suppressing effects of GLP-1 medications may diminish for some patients, leading to a gradual return of hunger, cravings, and food noise, though often less intense than pre-treatment levels.

If you are on long-term GLP-1 medication and notice your hunger or cravings returning slightly, this is a known phenomenon called the 'stable phase' transition. It does not necessarily mean the drug has failed. You may need to adjust your eating habits or discuss dose adjustments with your doctor. The return of hunger is often less severe than before treatment.

Combination therapy using atomoxetine and oxybutynin reduces OSA severity by approximately 60% by activating pharyngeal dilator muscles.

This combination drug is currently in clinical trials (Phase III) and not yet widely available. It targets the muscle function aspect of sleep apnea. If you are not a candidate for CPAP or weight loss drugs, you may want to ask your doctor about upcoming clinical trials for this specific combination.

Carbonic anhydrase inhibitors such as acetazolamide reduce OSA severity by 40-50% in patients with high loop gain.

If you have high loop gain OSA, ask your doctor about carbonic anhydrase inhibitors like acetazolamide. These can reduce your apnea severity by 40-50% by stabilizing your breathing control. Be aware of potential side effects like tingling or stomach upset.

Brown adipose tissue (BAT) activation and white-to-brown adipose tissue transformation reduce obesity risk by increasing energy expenditure and improving glucose homeostasis.

Focus on strategies that may support metabolic health and energy expenditure, such as exposure to cold or specific dietary patterns, as these may influence brown fat activity. However, consult a healthcare provider for personalized advice, as this is a complex physiological area.